bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S6 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Phosphoprotein changes induced by PQR309 in B cell lymphoma cell lines revealed using Reverse Phase Protein Array (RPPA) analysis.
Table S2 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

PQR309 activity, combinations of PQR309 with additional drugs, BCL2, MYC and TP53 status in lymphoma cell lines.
Supplementary Table 6B from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Associations of AR mRNA levels and individual genes and gene signatures (GS) in BC subtypes
Supplementary Table 6A from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Association of AR mRNA levels and individual genes and gene signatures (GS) in all BC patients
Supplementary Figure S2 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Flow cytometry gating for blood and ascites mononuclear cells. Forward and sideward scatter plots were used to set initial gates to identify lymphocytes and granulocyte populations in blood (A) and ascites (B). Dead cell population was identified using PI staining. Subsequent gates were set using isotype controls for all the fluorochromes used so that the bottom left quadrant had at least 99% of the gated cell population. An example of isotype gating for lymphocyte population stained using FITC and PE isotype is shown (C).
Supplementary Text from Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Authors: Lohavanichbutr Pawadee , Sakoda Lori C. , Amos Christopher I. , Arnold Susanne M. , Christiani David C. , Davies Michael P.A. , Field John K. , Haura Eric B. , Hung Rayjean J. , Kohno Takashi , Landi Maria Teresa , Liu Geoffrey , Liu Yi , Marcus Michael W. , O'Kane Grainne M. , Schabath Matthew B. , Shiraishi Kouya , Slone Stacey A. , Tardón Adonina , Yang Ping , Yoshida Kazushi , Zhang Ruyang , Zong Xuchen , Goodman Gary E. , Weiss Noel S. , Chen Chu
Published: April 2023

Description of the participant studies
'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

'Representative examples of primary tumors with discordant TP53 sequencing and p53 immunostaining results on tissue microarray. Two tumors with TP53 missense mutations (upper left and upper right) did not show appreciable nuclear accumulation of TP53. Note that the mutation in the tumor on the upper left (p.R282W) was detected in another sample from a different patient by IHC and the tumor on the upper right had 8 separate TP53 missense mutations detected, of unknown significance. Two additional tumors without missense mutations (one WT by sequencing on lower left, and one with an in-frame deletion on lower right) both showed nuclear accumulation of p53 protein by IHC in >10% of cells and were considered false positives. All photomicrographs are reduced from 200x.'
Supplementary Table S2 from Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Authors: Lohavanichbutr Pawadee , Sakoda Lori C. , Amos Christopher I. , Arnold Susanne M. , Christiani David C. , Davies Michael P.A. , Field John K. , Haura Eric B. , Hung Rayjean J. , Kohno Takashi , Landi Maria Teresa , Liu Geoffrey , Liu Yi , Marcus Michael W. , O'Kane Grainne M. , Schabath Matthew B. , Shiraishi Kouya , Slone Stacey A. , Tardón Adonina , Yang Ping , Yoshida Kazushi , Zhang Ruyang , Zong Xuchen , Goodman Gary E. , Weiss Noel S. , Chen Chu
Published: April 2023

Patient characteristics by study site
Table S1 from 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Authors: Quintela-Fandino Miguel , Lluch Ana , Manso Luis , Calvo Isabel , Cortes Javier , García-Saenz José Angel , Gil-Gil Miguel , Martinez-Jánez Noelia , Gonzalez-Martin Antonio , Adrover Encarna , de Andres Raquel , Viñas Gemma , Llombart-Cussac Antonio , Alba Emilio , Guerra Juan , Bermejo Begoña , Zamora Esther , Moreno-Anton Fernando , Pernas Simon Sonia , Carrato Alfredo , Lopez-Alonso Antonio , Escudero María José , Campo Ruth , Carrasco Eva , Palacios José , Mulero Francisca , Colomer Ramon
Published: April 2023

Table containing the inter-patient PET variability data
Supplemental Table 1 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Clinic-pathological findings of HCC patients.
Supplemental Figure 3 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Gain/loss of K19 function in HCC cells.
Supplementary Figure S2 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Study design for subject and genotype quality control.
Supplementary Materials Legend from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Legend for supplementary materials
Supplementary Figure S4 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Correlation between IGF2BP3 and ABCF1 in 9 ES cell lines and ABCF1 mRNA half-life in IGF2BP3-depleted cells
Table S1 from CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
Authors: Edwards Jarem , Wilmott James S. , Madore Jason , Gide Tuba Nur , Quek Camelia , Tasker Annie , Ferguson Angela , Chen Jinbiao , Hewavisenti Rehana , Hersey Peter , Gebhardt Thomas , Weninger Wolfgang , Britton Warwick J. , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Long Georgina V. , Scolyer Richard A. , Palendira Umaimainthan
Published: April 2023

Supplementary table with clinical data
Figure S1 from CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
Authors: Edwards Jarem , Wilmott James S. , Madore Jason , Gide Tuba Nur , Quek Camelia , Tasker Annie , Ferguson Angela , Chen Jinbiao , Hewavisenti Rehana , Hersey Peter , Gebhardt Thomas , Weninger Wolfgang , Britton Warwick J. , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Long Georgina V. , Scolyer Richard A. , Palendira Umaimainthan
Published: April 2023

Supplementary data on genomics
Figure S1 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

Training set to determine the optimal prognostic LDHA mRNA expression cut-off
Table S2 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Clinicopathological characteristics of all patients in the Rotterdam cohort and comparison between ISGhigh and ISGlow subgroups
Revised Suppl. Figure S1 from Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Authors: Odate Seiichi , Veschi Veronica , Yan Shuang , Lam Norris , Woessner Richard , Thiele Carol J.
Published: April 2023

Revised supplementary Figure S1.
Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
Authors: McCoach Caroline E. , Blakely Collin M. , Banks Kimberly C. , Levy Benjamin , Chue Ben M. , Raymond Victoria M. , Le Anh T. , Lee Christine E. , Diaz Joseph , Waqar Saiama N. , Purcell William T. , Aisner Dara L. , Davies Kurtis D. , Lanman Richard B. , Shaw Alice T. , Doebele Robert C.
Published: April 2023

Supplementary Figures 1,2, 3
Supplemental Tables from UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Authors: DeRyckere Deborah , Lee-Sherick Alisa B. , Huey Madeline G. , Hill Amanda A. , Tyner Jeffrey W. , Jacobsen Kristen M. , Page Lauren S. , Kirkpatrick Gregory G. , Eryildiz Fatma , Montgomery Stephanie A. , Zhang Weihe , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Table 1: Antibody Suppliers and Catalog Numbers Supplemental Table 2: Cell Cycle Profiles in Acute Leukemia Cell Lines Treated with UNC2025. Mean values, standard errors, and p values compared to vehicle treatment from 3 independent experiments are shown. (NS=Not Significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) Supplemental Table 3: Median Post-Treatment Survival in the 697 Minimal Residual Disease Model Supplemental Table 4: Brain and Plasma Concentrations in Swiss Albino Mice Following Administration of a Single Oral Dose of UNC2025. Supplemental Table 5: Median Post-Treatment Survival in the 697 Existent Disease Model
Table S3 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

IC50 summary of validated drug hits in SCCOHT cell lines.
Supplemental Methods from Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing
Authors: Roberts Brian S. , Hardigan Andrew A. , Moore Dianna E. , Ramaker Ryne C. , Jones Angela L. , Fitz-Gerald Meredith B. , Cooper Gregory M. , Wilcox C. Mel , Kimberly Robert P. , Myers Richard M.
Published: April 2023

Detailed methods including analysis
Supplementary Figures 1-5, Supplementary Tables 1-3, Supplementary References from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Authors: Smith Matthew A. , Licata Thomas , Lakhani Aliya , Garcia Marileila Varella , Schildhaus Hans-Ulrich , Vuaroqueaux Vincent , Halmos Balazs , Borczuk Alain C. , Chen Y. Ann , Creelan Benjamin C. , Boyle Theresa A. , Haura Eric B.
Published: April 2023

Figure S1: Adaptor knockdowns. A) 72hr titration of BKM120 in MET-amplified NSCLC cell lines analyzed by Cell Titer Glo 72 hr. Figure S2: Distribution of tumor types for PDX models used in MET:GRB2 PLA survey. Figure S3: Immunohistochemistry in PDX models and cell line controls A) H&E and IHC for MET and phospho-MET (Tyr1234/5) from non-treated control mice. Figure S4: Intratumoral heterogeneity of MET:GRB2 Signaling complexes in LXFA2165. Red foci represent MET:GRB2 PLA signal. Green = cytokeratin, Blue = DAPI. Figure S5: Regression model of MET:GRB2 PLA to tumor volume change. Supplemental Table 1: Summary of MET TKi sensitivity, phospho-MET western and MET:GRB2 complex presence in 12 cell line panel Supplemental Table 2: Mutations and Mutational Burden* Identified in Top 20 Lung Adenocarcinoma Mutations as Defined by TCGA (2). Supplemental Table 3: METÎ"ex14 Patient Characteristics
Table S1 from Establishing a Preclinical Multidisciplinary Board for Brain Tumors
Authors: Nimmervoll Birgit V. , Boulos Nidal , Bianski Brandon , Dapper Jason , DeCuypere Michael , Shelat Anang , Terranova Sabrina , Terhune Hope E. , Gajjar Amar , Patel Yogesh T. , Freeman Burgess B. , Onar-Thomas Arzu , Stewart Clinton F. , Roussel Martine F. , Guy R. Kipling , Merchant Thomas E. , Calabrese Christopher , Wright Karen D. , Gilbertson Richard J.
Published: April 2023

mouse models of supratentorial ependymoma and CPC and the number of cells implanted as allografts
Table S7. Immunohistochemical markers and gene rearrangements according to MYD88 variants. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

Statistically significant differences (p<0.05) are indicated with an asterisk (*). Among ABC patients, MYD88 mutant patients are compared as a whole to MYD88 WT patients and MYD88 L265P mutant patients are compared to the remainder of ABC patients. Among GCB patients, MYD88 mutant patients are compared as a whole to MYD88 WT patients.
Table S5. Cohort variants. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

This table presents all variants identified among our cohort by Lymphopanel NGS. Variant type and variant allele frequency (VAF) are indicated.
Table S2. Cell of origin according to MYD88 mutations. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

COO information according to the three techniques used in this study is given according to the various MYD88 variants present in our cohort.
Figure S7 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Expression of CD44 and CD24 in response to lapatinib.
Figure S4 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Lapatinib increases Jagged-1 expressing CSCs from MCF-7-HER2 cells.
Table S1 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Description of multiplex QIF panels
Figure S2 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Multiplexed fluorescence panels
Figure S1 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Validation of VISTA assay
Supplementary Data from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Authors: Garsed Dale W. , Alsop Kathryn , Fereday Sian , Emmanuel Catherine , Kennedy Catherine J. , Etemadmoghadam Dariush , Gao Bo , Gebski Val , Garès Valérie , Christie Elizabeth L. , Wouters Maartje C.A. , Milne Katy , George Joshy , Patch Ann-Marie , Li Jason , Arnau Gisela Mir , Semple Timothy , Gadipally Sreeja R. , Chiew Yoke-Eng , Hendley Joy , Mikeska Thomas , Zapparoli Giada V. , Amarasinghe Kaushalya , Grimmond Sean M. , Pearson John V. , Waddell Nicola , Hung Jillian , Stewart Colin J.R. , Sharma Raghwa , Allan Prue E. , Rambau Peter F. , McNally Orla , Mileshkin Linda , Hamilton Anne , Ananda Sumitra , Grossi Marisa , Cohen Paul A. , Leung Yee C. , Rome Robert M. , Beale Philip , Blomfield Penny , Friedlander Michael , Brand Alison , Dobrovic Alexander , Köbel Martin , Harnett Paul , Nelson Brad H. , Bowtell David D. L. , deFazio Anna
Published: April 2023

Revised Supplementary Data, containing Supplementary Methods, Supplementary Figures, Supplementary Tables Supplementary Figure S1. Outline of cohort selection and analyses. Supplementary Figure S2. Clinical response and therapy course of 96 patients with exceptional responses to chemotherapy. Supplementary Figure S3. Distribution and type of TP53 mutations. Supplementary Figure S4. RB1 protein expression altered by genomic inactivation. Supplementary Figure S5. Characterization of CD8 and Ki-67 in tumors according to homologous recombination mutation status. Supplementary Table S2 Immunohistochemical analysis: primary antibodies and staining conditions Supplementary Table S3 Homologous recombination and DNA repair panel Supplementary Table S6 Comparison of molecular alteration prevalence between clinical subgroups Supplementary Table S7 Patient characteristics of tissue microarray cohort
Supplemental Table 2 from Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Authors: Yang Zhe , Yang Nong , Ou Qiuxiang , Xiang Yi , Jiang Tao , Wu Xue , Bao Hua , Tong Xiaoling , Wang Xiaonan , Shao Yang W. , Liu Yunpeng , Wang Yan , Zhou Caicun
Published: April 2023

Supplemental Table 2
Supplementary Figures 1-10, Supplementary Materials and Methods, Supplementary References from Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
Authors: Muliaditan Tamara , Opzoomer James W. , Caron Jonathan , Okesola Mary , Kosti Paris , Lall Sharanpreet , Van Hemelrijck Mieke , Dazzi Francesco , Tutt Andrew , Grigoriadis Anita , Gillett Cheryl E. , Madden Stephen F. , Burchell Joy M. , Kordasti Shahram , Diebold Sandra S. , Spicer James F. , Arnold James N.
Published: April 2023

Supplementary Figure S1â",HO-1 expression in MMTV-PyMT tumors; Supplementary Figure S2â",Effects of SnMP and chemotherapy combination therapy; Supplementary Figure S3â",HO-1+ TAMs in murine models of breast cancer; Supplementary Figure S4â",Genetic inactivation and therapeutic inhibition of myeloid HO-1 in the MMTV-PyMT model; Supplementary Figure S5â",HO-1 in human cancer; Supplementary Figure S6â",tSNE clustering identifies stromal and epithelial cell types from breast cancer patient single-cell RNA sequencing data; Supplementary Figure 7â", Single cell RNA-Seq gene expression for checkpoint molecules grouped by inferred cell type; Supplementary Figure S8â",HO-1 protein in myeloid cells in human cancer; Supplementary Figure S9â", Comparative efficacies of therapeutically targeting HO-1 and PD-1 alongside paclitaxel treatment in 4T1 tumors; Supplementary Figure S10â",Improving checkpoint blockade therapy using SnMP.
Supplementary table S3 from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
Authors: van Kessel Kim E.M. , van der Keur Kirstin A. , Dyrskjøt Lars , Algaba Ferran , Welvaart Naeromy Y.C. , Beukers Willemien , Segersten Ulrika , Keck Bastian , Maurer Tobias , Simic Tatjana , Horstmann Marcus , Grimm Marc-Oliver , Hermann Gregers G. , Mogensen Karin , Hartmann Arndt , Harving Niels , Petersen Astrid C. , Jensen Jørgen B. , Junker Kerstin , Boormans Joost L. , Real Francisco X. , Malats Núria , Malmström Per-Uno , Ørntoft Torben F. , Zwarthoff Ellen C.
Published: April 2023

Supplementary Table S3. Distribution of the EAU category and administration of intravesical instillations per country. Between brackets the percentage (%) within each country is given.
Table S2 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Table S2 (Excel file). Full list of the genes included in the panel (not showed 6 reference genes: CLTC, GAPDH, GUSB, HPRT1, PGK1 and TUBB). Columns are as follows: 1) HUGO gene symbol; 2) shows association with miR-500a activity by ActMiR algorithm in TCGA dataset; 3) presence in PAM50 panel; 4) differentially expressed in MCF7 cells after modulation of miR-500a (overexpression of mimic or antagonist).
Supplementary figure S6 from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
Authors: van Kessel Kim E.M. , van der Keur Kirstin A. , Dyrskjøt Lars , Algaba Ferran , Welvaart Naeromy Y.C. , Beukers Willemien , Segersten Ulrika , Keck Bastian , Maurer Tobias , Simic Tatjana , Horstmann Marcus , Grimm Marc-Oliver , Hermann Gregers G. , Mogensen Karin , Hartmann Arndt , Harving Niels , Petersen Astrid C. , Jensen Jørgen B. , Junker Kerstin , Boormans Joost L. , Real Francisco X. , Malats Núria , Malmström Per-Uno , Ørntoft Torben F. , Zwarthoff Ellen C.
Published: April 2023

Supplementary figure S6. Progression-free survival curves in EAU high risk patients for (A) Intravesical instillations, (B) Grade, (C) FGFR3 and (D) GATA2. Progressive disease is defined as progression to stage T2 or higher stage disease. P-values (log-rank test) are indicated in each figure.
Supplementary Data from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Methods and Figures Supplemental Figure S1. Aurora kinase expression in Ewing sarcoma Supplemental Figure S2. Effects of cell growth on response to AZD-1152 as a function of duration of treatment. Supplemental Figure S3. Aurora kinase and FAK inhibitor combinations are synergistic in Ewing sarcoma cell lines Supplemental Figure S4. Response of Ewing cell lines treated with combinations of Aurora kinase and FAK inhibitors Supplemental Figure S5. Cell cycle and apoptotic effects of Aurora kinase B knock out in Ewing sarcoma cell lines Supplemental Figure S6. PYK2 is poorly expressed in Ewing sarcoma cells Supplemental Figure S7. Zebrafish and Murine studies
Table S1-S7 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Authors: Chang Matthew T. , Penson Alexander , Desai Neil B. , Socci Nicholas D. , Shen Ronglai , Seshan Venkatraman E. , Kundra Ritika , Abeshouse Adam , Viale Agnes , Cha Eugene K. , Hao Xueli , Reuter Victor E. , Rudin Charles M. , Bochner Bernard H. , Rosenberg Jonathan E. , Bajorin Dean F. , Schultz Nikolaus , Berger Michael F. , Iyer Gopa , Solit David B. , Al-Ahmadie Hikmat A. , Taylor Barry S.
Published: April 2023

Supplementary Table 1: Patients and sequencing platforms utilized. Supplementary Table 2: Clinical annotation of the cohort. Supplementary Table 3: MSK-IMPACT gene content Supplementary Table 4: Gene-level DNA copy number Supplementary Table 5: Cardinal and key lesions in SCCBs Supplementary Table 6: Somatic mutations. Supplementary Table 7: Purity, ploidy, and genome doubling.
Figure S7 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Authors: Chang Matthew T. , Penson Alexander , Desai Neil B. , Socci Nicholas D. , Shen Ronglai , Seshan Venkatraman E. , Kundra Ritika , Abeshouse Adam , Viale Agnes , Cha Eugene K. , Hao Xueli , Reuter Victor E. , Rudin Charles M. , Bochner Bernard H. , Rosenberg Jonathan E. , Bajorin Dean F. , Schultz Nikolaus , Berger Michael F. , Iyer Gopa , Solit David B. , Al-Ahmadie Hikmat A. , Taylor Barry S.
Published: April 2023

Supplementary Figure 7: Therapeutically actionable lesions.
Supplementary Figure 2 from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
Authors: Pietrantonio Filippo , Fucà Giovanni , Morano Federica , Gloghini Annunziata , Corso Simona , Aprile Giuseppe , Perrone Federica , De Vita Ferdinando , Tamborini Elena , Tomasello Gianluca , Gualeni Ambra Vittoria , Ongaro Elena , Busico Adele , Giommoni Elisa , Volpi Chiara Costanza , Laterza Maria Maddalena , Corallo Salvatore , Prisciandaro Michele , Antista Maria , Pellegrinelli Alessandro , Castagnoli Lorenzo , Pupa Serenella M. , Pruneri Giancarlo , de Braud Filippo , Giordano Silvia , Cremolini Chiara , Di Bartolomeo Maria
Published: April 2023

Kaplan Meier estimates of PFS according to HER2 IHC expression (2+ versus 3+) in patients molecularly selected by the AMNESIA panel, i.e. in absence of EGFR/MET/KRAS/PI3K mutations and EGFR/MET/KRAS amplifications.
Supplementary Table 1 from Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
Authors: Wang Qiong J. , Yu Zhiya , Hanada Ken-ichi , Patel Krishna , Kleiner David , Restifo Nicholas P. , Yang James C.
Published: April 2023

HLA Genotyping of renal cell cancer cell lines
Figure S2 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Authors: Chang Matthew T. , Penson Alexander , Desai Neil B. , Socci Nicholas D. , Shen Ronglai , Seshan Venkatraman E. , Kundra Ritika , Abeshouse Adam , Viale Agnes , Cha Eugene K. , Hao Xueli , Reuter Victor E. , Rudin Charles M. , Bochner Bernard H. , Rosenberg Jonathan E. , Bajorin Dean F. , Schultz Nikolaus , Berger Michael F. , Iyer Gopa , Solit David B. , Al-Ahmadie Hikmat A. , Taylor Barry S.
Published: April 2023

Supplementary Figure 2: Enrichment of biallelic RB1 in SCCBs.
Supplementary Methods, Supplementary Figures S1, S2, Supplementary Tables S1-S3 from Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
Authors: Sperger Jamie M. , Strotman Lindsay N. , Welsh Allison , Casavant Benjamin P. , Chalmers Zachery , Horn Sacha , Heninger Erika , Thiede Stephanie M. , Tokar Jacob , Gibbs Benjamin K. , Guckenberger David J. , Carmichael Lakeesha , Dehm Scott M. , Stephens Philip J. , Beebe David J. , Berry Scott M. , Lang Joshua M.
Published: April 2023

This supplementary file contains additional Matierials and Methods detailing the VERSA process. Figure S1. Longitudinal analysis of capture efficiency of Epcam antibody. Figure S2. Multi-parametric analysis of gene expression, genomic profiling and AR protein analysis from captured CTCs. Table S1. Catalog numbers of primers used for quantitative qPCR. Table S2. Patients characteristics for patients 1-17. Table S3. Patient characteristics from patients 18-43
Figure S5 from The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis
Authors: Deel Michael D. , Slemmons Katherine K. , Hinson Ashley R. , Genadry Katia C. , Burgess Breanne A. , Crose Lisa E.S. , Kuprasertkul Nina , Oristian Kristianne M. , Bentley Rex C. , Linardic Corinne M.
Published: April 2023

Validation of Dox-inducible TAZ shRNA constructs in Rh28 cells.
Supplementary Figure 3 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Authors: Woroniecka Karolina , Chongsathidkiet Pakawat , Rhodin Kristen , Kemeny Hanna , Dechant Cosette , Farber S. Harrison , Elsamadicy Aladine A. , Cui Xiuyu , Koyama Shohei , Jackson Christina , Hansen Landon J. , Johanns Tanner M. , Sanchez-Perez Luis , Chandramohan Vidyalakshmi , Yu Yen-Rei Andrea , Bigner Darell D. , Giles Amber , Healy Patrick , Dranoff Glenn , Weinhold Kent J. , Dunn Gavin P. , Fecci Peter E.
Published: April 2023

Co-expression of immune checkpoints in murine glioma
Supplementary Movie S2 from Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer
Authors: Chen Chun-Han , Changou Chun A. , Hsieh Tsung-Han , Lee Yu-Ching , Chu Cheng-Ying , Hsu Kai-Cheng , Wang Hao-Ching , Lin Yu-Chen , Lo Yan-Ni , Liu Yun-Ru , Liou Jing-Ping , Yen Yun
Published: April 2023

Effect of MPT0L145 on endosomal functions.
Supplementary Figure 1 from Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Authors: Huang Yu-Fang , Wu Yi-Hui , Cheng Wen-Fang , Peng Shu-Ling , Shen Wan-Lin , Chou Cheng-Yang
Published: April 2023

(A) Top 10 up-regulation genes expressed in ascites from ovarian cancers in our preliminary proteomic study. (B) Ascitic vitamin D binding protein (DBP) levels between groups of benign gynecologic disease, low malignant potential (LMP) ovarian tumor, and invasive ovarian cancer.
Figure S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Authors: Ribba Benjamin , Boetsch Christophe , Nayak Tapan , Grimm Hans Peter , Charo Jehad , Evers Stefan , Klein Christian , Tessier Jean , Charoin Jean Eric , Phipps Alex , Pisa Pavel , Teichgräber Volker
Published: April 2023

Supplementary Figure S2: Values of the estimated uptake ratio of the expected extravasation/penetration parameter from [8] based on LST174 data across indications in the 8 CEA+ patients.
Supp Figure S5 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S5
Supplemental Figure Legends from Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
Authors: Stiff Andrew , Trikha Prashant , Mundy-Bosse Bethany , McMichael Elizabeth , Mace Thomas A. , Benner Brooke , Kendra Kari , Campbell Amanda , Gautam Shalini , Abood David , Landi Ian , Hsu Vincent , Duggan Megan , Wesolowski Robert , Old Matthew , Howard John Harrison , Yu Lianbo , Stasik Nancy , Olencki Thomas , Muthusamy Natarajan , Tridandapani Susheela , Byrd John C. , Caligiuri Michael , Carson William E.
Published: April 2023

Supplemental Figure Legends
Supplemental Fig 1 from Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Authors: Tang Chad , Welsh James W. , de Groot Patricia , Massarelli Erminia , Chang Joe Y. , Hess Kenneth R. , Basu Sreyashi , Curran Michael A. , Cabanillas Maria E. , Subbiah Vivek , Fu Siqing , Tsimberidou Apostolia M. , Karp Daniel , Gomez Daniel R. , Diab Adi , Komaki Ritsuko , Heymach John V. , Sharma Padmanee , Naing Aung , Hong David S.
Published: April 2023

CD8+ T cell expression
Supplementary Table S3. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
Authors: Rossi Giovanna , Mu Zhaomei , Rademaker Alfred W. , Austin Laura K. , Strickland Kimberly S. , Costa Ricardo Lima Barros , Nagy Rebecca J. , Zagonel Vittorina , Taxter Timothy J. , Behdad Amir , Wehbe Firas H. , Platanias Leonidas C. , Gradishar William J. , Cristofanilli Massimo
Published: April 2023

Distribution of the patients according to the change of treatment based on ctDNA findings.
Supplementary Materials and Methods from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Authors: Haynes Jennifer , McKee Trevor D. , Haller Andrew , Wang Yadong , Leung Cherry , Gendoo Deena M.A. , Lima-Fernandes Evelyne , Kreso Antonija , Wolman Robin , Szentgyorgyi Eva , Vines Douglass C. , Haibe-Kains Benjamin , Wouters Bradly G. , Metser Ur , Jaffray David A. , Smith Myles , O'Brien Catherine A.
Published: April 2023

Supplementary Materials and Methods (unmarked)
supplemental figure legend from The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma
Authors: Zhong Qian , Liu Zhi-Hua , Lin Zhi-Rui , Hu Ze-Dong , Yuan Li , Liu Yan-min , Zhou Ai-Jun , Xu Li-Hua , Hu Li-Juan , Wang Zi-Feng , Guan Xin-Yuan , Hao Jia-Jie , Lui Vivian W.Y. , Guo Ling , Mai Hai-Qiang , Chen Ming-Yuan , Han Fei , Xia Yun-Fei , Grandis Jennifer R. , Zhang Xing , Zeng Mu-Sheng
Published: April 2023

supplemental figure legend
Supplementary Methods from Intratumoral HPV16-Specific T Cells Constitute a Type I–Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer
Authors: Welters Marij J.P. , Ma Wenbo , Santegoets Saskia J.A.M. , Goedemans Renske , Ehsan Ilina , Jordanova Ekaterina S. , van Ham Vanessa J. , van Unen Vincent , Koning Frits , van Egmond Sylvia I. , Charoentong Pornpimol , Trajanoski Zlatko , van der Velden Lilly-Ann , van der Burg Sjoerd H.
Published: April 2023

Supplementary Methods and Tables Supplementary Table S1. Patient characteristics Supplementary Table S2. Antibodies with isotope tags used in CyTOF analysis Supplementary Table S3. Standard therapy of HPV16+ OPSCC patients
supplemental data 1 from The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma
Authors: Zhong Qian , Liu Zhi-Hua , Lin Zhi-Rui , Hu Ze-Dong , Yuan Li , Liu Yan-min , Zhou Ai-Jun , Xu Li-Hua , Hu Li-Juan , Wang Zi-Feng , Guan Xin-Yuan , Hao Jia-Jie , Lui Vivian W.Y. , Guo Ling , Mai Hai-Qiang , Chen Ming-Yuan , Han Fei , Xia Yun-Fei , Grandis Jennifer R. , Zhang Xing , Zeng Mu-Sheng
Published: April 2023

RARS-MAD1L1 gDNA fusion sequence by Sanger Sequencing
Supplementary Table 2. from BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Authors: Bolyard Chelsea , Meisen W. Hans , Banasavadi-Siddegowda Yeshavanth , Hardcastle Jayson , Yoo Ji Young , Wohleb Eric S. , Wojton Jeffrey , Yu Jun-Ge , Dubin Samuel , Khosla Maninder , Xu Bo , Smith Jonathan , Alvarez-Breckenridge Christopher , Pow-anpongkul Pete , Pichiorri Flavia , Zhang Jianying , Old Matthew , Zhu Dan , Van Meir Erwin G. , Godbout Jonathan P. , Caligiuri Michael A. , Yu Jianhua , Kaur Balveen
Published: April 2023

List of genes differentially induced ({greater than or equal to} 1.5 fold) in macrophages cultured with rHSVQ1 (Q) vs. RAMBO (R) infected glioma cells (UI, uninfected).
Supplementary Figure 1. from BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Authors: Bolyard Chelsea , Meisen W. Hans , Banasavadi-Siddegowda Yeshavanth , Hardcastle Jayson , Yoo Ji Young , Wohleb Eric S. , Wojton Jeffrey , Yu Jun-Ge , Dubin Samuel , Khosla Maninder , Xu Bo , Smith Jonathan , Alvarez-Breckenridge Christopher , Pow-anpongkul Pete , Pichiorri Flavia , Zhang Jianying , Old Matthew , Zhu Dan , Van Meir Erwin G. , Godbout Jonathan P. , Caligiuri Michael A. , Yu Jianhua , Kaur Balveen
Published: April 2023

Ewing sarcoma subcutaneous tumors stained for CD68+ macrophages, with hematoxylin counterstain.
Supplementary Figure S3 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
Authors: Laszlo Viktoria , Valko Zsuzsanna , Kovacs Ildiko , Ozsvar Judit , Hoda Mir Alireza , Klikovits Thomas , Lakatos Dora , Czirok Andras , Garay Tamas , Stiglbauer Alexander , Helbich Thomas H. , Gröger Marion , Tovari Jozsef , Klepetko Walter , Pirker Christine , Grusch Michael , Berger Walter , Hilberg Frank , Hegedus Balazs , Dome Balazs
Published: April 2023

Impact of nintedanib on phosphorylation of target RTKs' downstream signaling
Supplementary figure S1 from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Authors: Hart Christopher D. , Vignoli Alessia , Tenori Leonardo , Uy Gemma Leonora , Van To Ta , Adebamowo Clement , Hossain Syed Mozammel , Biganzoli Laura , Risi Emanuela , Love Richard R. , Luchinat Claudio , Di Leo Angelo
Published: April 2023

Receiver operator characteristic (ROC) analysis of the RF risk score as a predictor of relapse in the initial cohort, for CPMG spectra: A) training set; B) validation set.
Supplementary Table S2 from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Authors: Hart Christopher D. , Vignoli Alessia , Tenori Leonardo , Uy Gemma Leonora , Van To Ta , Adebamowo Clement , Hossain Syed Mozammel , Biganzoli Laura , Risi Emanuela , Love Richard R. , Luchinat Claudio , Di Leo Angelo
Published: April 2023

Comparison of individual metabolite concentrations in arbitrary units in the serum NMR spectra of relapsing and non-relapsing EBC patients. Adjusted P-values for the comparison of relapsing and non-relapsing EBC Adjusted P-values are for the significance of any difference between EBC and MBC. MAD = median absolute deviation.
Table S5 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Univariable Cox Regression Analysis of the stromal immunotype, Clinical variables, and Survival in the Training Cohort, Testing cohort and Validation Cohort
Table S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

Table S1
Supplementary Figure Legends from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Supplementary Figure Legends
Figure S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Correlate Immunotype with disease-free survival in training cohort, testing cohort and validation cohort
Supplementary tables and references from Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Authors: Jardim Denis L. , de Melo Gagliato Débora , Giles Francis J. , Kurzrock Razelle
Published: April 2023

Includes supplementary tables referred on main text and additional references
Public Code from A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Authors: Song Jiangdian , Shi Jingyun , Dong Di , Fang Mengjie , Zhong Wenzhao , Wang Kun , Wu Ning , Huang Yanqi , Liu Zhenyu , Cheng Yue , Gan Yuncui , Zhou Yongzhao , Zhou Ping , Chen Bojiang , Liang Changhong , Liu Zaiyi , Li Weimin , Tian Jie
Published: April 2023

Public access algorithms and source code in this study.
Supplementary Table 3 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Association of clinical patient characteristics with molecular subtypes
Table S3 from Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Bang Yung-Jue , Cho Jae Yong , Kim Yeul Hong , Kim Jin Won , Di Bartolomeo Maria , Ajani Jaffer A. , Yamaguchi Kensei , Balogh Agnes , Sanchez Teresa , Moehler Markus
Published: April 2023

Table S3 shows Subsequent Therapies